✦ LIBER ✦

Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma

✍ Scribed by William H. Morrison; Robert M. Byers; Adam S. Garden; Harry L. Evans; K. Kian Ang; Lester J. Peters

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 880 KB
Volume: 76
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950715)76:2<319::aid-cncr2820760224>3.0.co;2-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cutaneous malignant melanoma of the head

Cutaneous malignant melanoma of the head and neck

✍ Neil H. Cox; Stephen K. Jones; Rona M Mackie 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

Therapeutic lymphadenectomy in melanomas

Therapeutic lymphadenectomy in melanomas of the head and neck

✍ Dr. Willem Van De Vrie; Dr. Alexander M. M. Eggermont; Dr. Wim L. J. Van Putten; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB

This retrospective study describes patients with locoregionally metastasized melanoma of the head and neck. All patients underwent a therapeutic lymph node dissection. The 3-year survival rate was 35%. Duration of disease-free interval, number of lymph nodes involved, and extent of neck dissection p

Docetaxel: A therapeutic option in the t

Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma : Report of 9 patients

✍ Tohru Nagano; Yozo Yamada; Tetsuya Ikeda; Haruhisa Kanki; Tsuneyoshi Kamo; Chika 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

## Abstract ## BACKGROUND. Effective treatment options are limited for patients with cutaneous angiosarcoma (AS). Docetaxel, a member of the taxane family of drugs, reportedly has been effective in the treatment of lung, head and neck, and breast cancers. Another taxane drug, paclitaxel, reportedl

Preoperative radiotherapy and bevacizuma

Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: Two case studies

✍ Bridget F. Koontz; Edward F. Miles; Mary Ann D. Rubio; John F. Madden; Samuel R. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

## Abstract ## Background. Angiosarcoma of the face is a vascular tumor with poor local control and short median survival despite standard treatment. Bevacizumab is a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), which can inhibit tumor growth. It is synergistic with

Cutaneous angiosarcoma of the scalp : A

Cutaneous angiosarcoma of the scalp : A multidisciplinary approach

✍ Timothy M. Pawlik; Augusto F. Paulino; Cornelius J. Mcginn; Laurence H. Baker; D 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB

## Abstract ## BACKGROUND Angiosarcoma is a malignant tumor of vascular endothelial cells that arises in the head and neck. It is a rare, difficult to treat, and lethal tumor. ## METHODS Clinical data from patients who were diagnosed with angiosarcoma of the scalp between 1975 and 2002 at the Un

Superficial parotidectomy in the treatme

Superficial parotidectomy in the treatment of cutaneous melanoma of the head and neck

✍ L. C. Barr; A. I. Skene; S. Fish; J. M. Thomas 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 2 views